Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa.
<h4>Background</h4> <p>In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd),...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2018
|
| _version_ | 1826283993142657024 |
|---|---|
| author | Taylor, W Naw, H Maitland, K Williams, T Kapulu, M D'Alessandro, U Berkley, J Bejon, P Okebe, J Achan, J Amambua, A Affara, M Nwakanma, D van Geertruyden, J Mavoko, M Lutumba, P Matangila, J Brasseur, P Piola, P Randremanana, R Lasry, E Fanello, C Onyamboko, M Schramm, B Yah, Z Jones, J Fairhurst, R Diakite, M Malenga, G Molyneux, M Rwagacondo, C Obonyo, C Gadisa, E Aseffa, A Loolpapit, M Henry, M Dorsey, G John, C Sirima, S Barnes, K Kremsner, P Day, N White, N Mukaka, M |
| author_facet | Taylor, W Naw, H Maitland, K Williams, T Kapulu, M D'Alessandro, U Berkley, J Bejon, P Okebe, J Achan, J Amambua, A Affara, M Nwakanma, D van Geertruyden, J Mavoko, M Lutumba, P Matangila, J Brasseur, P Piola, P Randremanana, R Lasry, E Fanello, C Onyamboko, M Schramm, B Yah, Z Jones, J Fairhurst, R Diakite, M Malenga, G Molyneux, M Rwagacondo, C Obonyo, C Gadisa, E Aseffa, A Loolpapit, M Henry, M Dorsey, G John, C Sirima, S Barnes, K Kremsner, P Day, N White, N Mukaka, M |
| author_sort | Taylor, W |
| collection | OXFORD |
| description | <h4>Background</h4> <p>In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa.</p> <h4>Methods</h4> <p>Using data on the anti-infectivity efficacy and tolerability of primaquine (PQ), the epidemiology of anaemia, and the risks of PQ-induced acute haemolytic anaemia (AHA) and clinically significant anaemia (CSA), we prospectively defined therapeutic-dose ranges of 0.15–0.4 mg PQ base/kg for children aged 1–5 years and 0.15–0.5 mg PQ base/kg for individuals aged ≥6 years (therapeutic indices 2.7 and 3.3, respectively). We chose 1.25 mg PQ base for infants aged 6–11 months because they have the highest rate of baseline anaemia and the highest risks of AHA and CSA. We modelled an anthropometric database of 661,979 African individuals aged ≥6 months (549,127 healthy individuals, 28,466 malaria patients and 84,386 individuals with other infections/illnesses) by the Box–Cox transformation power exponential and tested PQ doses of 1–15 mg base, selecting dosing groups based on calculated mg/kg PQ doses.</p> <h4>Results</h4> <p>From the Box–Cox transformation power exponential model, five age categories were selected: (i) 6–11 months (n = 39,886, 6.03%), (ii) 1–5 years (n = 261,036, 45.46%), (iii) 6–9 years (n = 20,770, 3.14%), (iv) 10–14 years (n = 12,155, 1.84%) and (v) ≥15 years (n = 328,132, 49.57%) to receive 1.25, 2.5, 5, 7.5 and 15 mg PQ base for corresponding median (1st and 99th centiles) mg/kg PQ base of: (i) 0.16 (0.12–0.25), (ii) 0.21 (0.13–0.37), (iii) 0.25 (0.16–0.38), (iv) 0.26 (0.15–0.38) and (v) 0.27 (0.17–0.40). The proportions of individuals predicted to receive optimal therapeutic PQ doses were: 73.2 (29,180/39,886), 93.7 (244,537/261,036), 99.6 (20,690/20,770), 99.4 (12,086/12,155) and 99.8% (327,620/328,132), respectively.</p> <h4>Conclusions</h4> <p>We plan to test the safety of this age-based dosing regimen in a large randomised placebo-controlled trial (ISRCTN11594437) of uncomplicated falciparum malaria in G6PDd African children aged 0.5 − 11 years. If the regimen is safe and demonstrates adequate pharmacokinetics, it should be used to support malaria elimination.</p> |
| first_indexed | 2024-03-07T01:07:10Z |
| format | Journal article |
| id | oxford-uuid:8bc0fef9-556d-436c-9fba-f0680818c39c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:07:10Z |
| publishDate | 2018 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:8bc0fef9-556d-436c-9fba-f0680818c39c2022-03-26T22:40:10ZSingle low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8bc0fef9-556d-436c-9fba-f0680818c39cEnglishSymplectic Elements at OxfordBioMed Central2018Taylor, WNaw, HMaitland, KWilliams, TKapulu, MD'Alessandro, UBerkley, JBejon, POkebe, JAchan, JAmambua, AAffara, MNwakanma, Dvan Geertruyden, JMavoko, MLutumba, PMatangila, JBrasseur, PPiola, PRandremanana, RLasry, EFanello, COnyamboko, MSchramm, BYah, ZJones, JFairhurst, RDiakite, MMalenga, GMolyneux, MRwagacondo, CObonyo, CGadisa, EAseffa, ALoolpapit, MHenry, MDorsey, GJohn, CSirima, SBarnes, KKremsner, PDay, NWhite, NMukaka, M <h4>Background</h4> <p>In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa.</p> <h4>Methods</h4> <p>Using data on the anti-infectivity efficacy and tolerability of primaquine (PQ), the epidemiology of anaemia, and the risks of PQ-induced acute haemolytic anaemia (AHA) and clinically significant anaemia (CSA), we prospectively defined therapeutic-dose ranges of 0.15–0.4 mg PQ base/kg for children aged 1–5 years and 0.15–0.5 mg PQ base/kg for individuals aged ≥6 years (therapeutic indices 2.7 and 3.3, respectively). We chose 1.25 mg PQ base for infants aged 6–11 months because they have the highest rate of baseline anaemia and the highest risks of AHA and CSA. We modelled an anthropometric database of 661,979 African individuals aged ≥6 months (549,127 healthy individuals, 28,466 malaria patients and 84,386 individuals with other infections/illnesses) by the Box–Cox transformation power exponential and tested PQ doses of 1–15 mg base, selecting dosing groups based on calculated mg/kg PQ doses.</p> <h4>Results</h4> <p>From the Box–Cox transformation power exponential model, five age categories were selected: (i) 6–11 months (n = 39,886, 6.03%), (ii) 1–5 years (n = 261,036, 45.46%), (iii) 6–9 years (n = 20,770, 3.14%), (iv) 10–14 years (n = 12,155, 1.84%) and (v) ≥15 years (n = 328,132, 49.57%) to receive 1.25, 2.5, 5, 7.5 and 15 mg PQ base for corresponding median (1st and 99th centiles) mg/kg PQ base of: (i) 0.16 (0.12–0.25), (ii) 0.21 (0.13–0.37), (iii) 0.25 (0.16–0.38), (iv) 0.26 (0.15–0.38) and (v) 0.27 (0.17–0.40). The proportions of individuals predicted to receive optimal therapeutic PQ doses were: 73.2 (29,180/39,886), 93.7 (244,537/261,036), 99.6 (20,690/20,770), 99.4 (12,086/12,155) and 99.8% (327,620/328,132), respectively.</p> <h4>Conclusions</h4> <p>We plan to test the safety of this age-based dosing regimen in a large randomised placebo-controlled trial (ISRCTN11594437) of uncomplicated falciparum malaria in G6PDd African children aged 0.5 − 11 years. If the regimen is safe and demonstrates adequate pharmacokinetics, it should be used to support malaria elimination.</p> |
| spellingShingle | Taylor, W Naw, H Maitland, K Williams, T Kapulu, M D'Alessandro, U Berkley, J Bejon, P Okebe, J Achan, J Amambua, A Affara, M Nwakanma, D van Geertruyden, J Mavoko, M Lutumba, P Matangila, J Brasseur, P Piola, P Randremanana, R Lasry, E Fanello, C Onyamboko, M Schramm, B Yah, Z Jones, J Fairhurst, R Diakite, M Malenga, G Molyneux, M Rwagacondo, C Obonyo, C Gadisa, E Aseffa, A Loolpapit, M Henry, M Dorsey, G John, C Sirima, S Barnes, K Kremsner, P Day, N White, N Mukaka, M Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title_full | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title_fullStr | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title_full_unstemmed | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title_short | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. |
| title_sort | single low dose primaquine for blocking transmission of plasmodium falciparum malaria a proposed model derived age based regimen for sub saharan africa |
| work_keys_str_mv | AT taylorw singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT nawh singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT maitlandk singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT williamst singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT kapulum singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT dalessandrou singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT berkleyj singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT bejonp singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT okebej singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT achanj singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT amambuaa singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT affaram singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT nwakanmad singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT vangeertruydenj singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT mavokom singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT lutumbap singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT matangilaj singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT brasseurp singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT piolap singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT randremananar singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT lasrye singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT fanelloc singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT onyambokom singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT schrammb singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT yahz singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT jonesj singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT fairhurstr singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT diakitem singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT malengag singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT molyneuxm singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT rwagacondoc singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT obonyoc singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT gadisae singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT aseffaa singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT loolpapitm singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT henrym singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT dorseyg singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT johnc singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT sirimas singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT barnesk singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT kremsnerp singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT dayn singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT whiten singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica AT mukakam singlelowdoseprimaquineforblockingtransmissionofplasmodiumfalciparummalariaaproposedmodelderivedagebasedregimenforsubsaharanafrica |